161 related articles for article (PubMed ID: 17090304)
1. BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility.
Zheng X; Güller S; Beissert T; Puccetti E; Ruthardt M
BMC Cancer; 2006 Nov; 6():262. PubMed ID: 17090304
[TBL] [Abstract][Full Text] [Related]
2. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
3. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
Daubon T; Rochelle T; Bourmeyster N; Génot E
Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
[TBL] [Abstract][Full Text] [Related]
4. Rho family GTPases regulate VEGF-stimulated endothelial cell motility.
Soga N; Namba N; McAllister S; Cornelius L; Teitelbaum SL; Dowdy SF; Kawamura J; Hruska KA
Exp Cell Res; 2001 Sep; 269(1):73-87. PubMed ID: 11525641
[TBL] [Abstract][Full Text] [Related]
5. Frequencies of the breakpoint cluster region types of the BCR/ABL fusion gene in Mexican Mestizo patients with chronic myelogenous leukemia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ
Rev Invest Clin; 2004; 56(5):605-8. PubMed ID: 15776864
[TBL] [Abstract][Full Text] [Related]
6. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
[TBL] [Abstract][Full Text] [Related]
7. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
[TBL] [Abstract][Full Text] [Related]
8. Generation of the BCR/ABL fusion gene in a Philadelphia chromosome-negative chronic myeloid leukaemia: insertion of 5.6 Mb of 9q34 into the BCR region of chromosome 22.
Valle L; Fernández V; Pérez-Pons C; Sánchez FG; Benítez J; Urioste M
Hematol Oncol; 2006 Jun; 24(2):86-8. PubMed ID: 16598834
[TBL] [Abstract][Full Text] [Related]
9. [The different signal patterns of two FISH probes in the FISH detection of Ph-positive leukemia and their clinical significance].
Jiang H; Xue YQ; Pan JL; Zhang J; Dai HP; Wu YF; Wang Y; Shen J; Chen SN
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Apr; 27(2):166-70. PubMed ID: 20376798
[TBL] [Abstract][Full Text] [Related]
10. [New approach in the diagnosis and monitoring of treatment in chronic myelogenous leukemia].
Matolcsy A
Orv Hetil; 2004 Dec; 145(52):2603-9. PubMed ID: 15724695
[TBL] [Abstract][Full Text] [Related]
11. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl.
Harnois T; Constantin B; Rioux A; Grenioux E; Kitzis A; Bourmeyster N
Oncogene; 2003 Sep; 22(41):6445-54. PubMed ID: 14508524
[TBL] [Abstract][Full Text] [Related]
12. Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
Lund HL; Hughesman CB; McNeil K; Clemens S; Hocken K; Pettersson R; Karsan A; Foster LJ; Haynes C
Anal Bioanal Chem; 2016 Feb; 408(4):1079-94. PubMed ID: 26631023
[TBL] [Abstract][Full Text] [Related]
13. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
[TBL] [Abstract][Full Text] [Related]
14. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
15. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH.
Kim YR; Cho HI; Yoon SS; Park S; Kim BK; Lee YK; Chun H; Kim HC; Lee DS
Genes Chromosomes Cancer; 2005 May; 43(1):37-44. PubMed ID: 15723338
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
18. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
19. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
Korus M; Mahon GM; Cheng L; Whitehead IP
Oncogene; 2002 Jul; 21(30):4601-12. PubMed ID: 12096337
[TBL] [Abstract][Full Text] [Related]
20. The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent manner.
Laurent CE; Smithgall TE
Exp Cell Res; 2004 Sep; 299(1):188-98. PubMed ID: 15302586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
